- Home
- CGBD vs OCS Comparison
CGBD vs OCS Comparison
Compare CGBD & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGBD | OCS |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.5M | 732.4M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGBD | OCS |
|---|---|---|
| Price | $11.45 | $13.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $12.92 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 546.3K | 234.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.74 | $466.06 |
| Revenue Next Year | $1.80 | $479.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $10.52 |
| 52 Week High | $14.00 | $34.48 |
Technical Indicators
Market Signals| Indicator | CGBD | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 56.15 |
| Support Level | $10.53 | $10.63 |
| Resistance Level | $11.47 | $13.28 |
| Average True Range (ATR) | 0.26 | 0.51 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 96.15 | 73.40 |
Price Performance
Historical ComparisonAbout CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.